Infection Update
Quinolones News

An international study shows that critical illness does not alter levofloxacin pharmacokinetics
(January 29, 2016)

Optimal treatment with 15 mg/kg levofloxacin daily is effective for active or latent MDR TB in children in the Federated States of Micronesia and Republic of the Marshall Islands
(January 29, 2016)

A combination of levofloxacin and colistin is bactericidal against colistin-susceptible Acinetobacter baumannii
(January 29, 2016)

The latest guidelines for the management of H. pylori infection in Italy recommend 10-day levofloxacin-amoxicillin after the failure of first-line therapy
(December 18, 2015)

New French guidelines recommend a levofloxacin combination as an empirical anti-infective therapy
(December 18, 2015)

Japanese demonstrate the excellent efficacy of levofloxacin against S. pneumoniae
(March 20, 2015)

A 5-day 750mg levofloxacin course is as effective as a 7-14 day regimen in patients with community-acquired pneumonia (CAP) in China
(September 12, 2014)

Update of the Practice Guidelines for the Diagnosis and Managment of Skin and Soft Tissue Infections
(July 11, 2014)

Sign up for Updates
What's New

Review Journal “Penetration” Special Issue 2015
The special 2015 edition of Penetration celebrates more than two decades of continuous use of the extremely effective and globally useful antimicrobial, levofloxacin. This issue summarizes the reviews and interviews published in all issues of Penetration, including latest data reported through 2015.
(July 30, 2015)

Optimal Strategic Therapy for Community-Acquired Pneumonia: Levofloxacin at the Forefront of Fluoroquinolone CAP Therapy
(Chaired by Dr. Moh. Arifin Nawas, SpP(K), MARS)
(February 17, 2015)

New Treatment Strategies for the Eradication of Helicobacter pylori—Combating the Global Trend of Antibiotic Resistance
(November 7, 2013)

Levofloxacin: a Mainstay of Fluoroquinolone-Based Therapy—After Twenty Years of Use, Levofloxacin Remains Safe and Effective
(Moderated by Kurt G. Naber, MD, PhD)
(September 4, 2013)

Learning in Depth

Viewing Infectious Respiratory Disease
(Supervised by Prof. Jiro Fujita, MD, PhD, ACCP)

Effect of Combination of Levofloxacin and
Meropenem against Pseudomonas aeruginosa

(Supervised by Prof. Kazuhiro Tateda, MD, PhD)

The Treatment of Community-Acquired Pneumonia with Consideration of Mycobacterium tuberculosis: Risk Management in the Treatment of Pneumonia-Avoiding the Masking of TB by Antimicrobials
(Co-Chaired by Thomas Chang-Yao Tsao, MD, PhD and Shang-Jyh Kao, MD)

©1998- BIOMEDIS International, Ltd. All rights reserved. Reproduction in any manner in whole or part prohibited.